Is OmniAb, Inc. (OABI) Overvalued?
We dive into why OmniAb, Inc. (OABI) could be considered overvalued on 2026-08-19, based on AAII’s Value Score and Grade.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company’s technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners’ drug development efforts. Its OmniAb platform’s Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb’s antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Commentary & Analysis
Does OmniAb, Inc. (OABI) Have Momentum?
With data as of August 19, 2026, we examine if OmniAb, Inc.(OABI) is consistently building momentum based on AAII's A+ Investor Momentum and Value Scores and Grades.Rosalio Madrigal
Why OmniAb, Inc.’s (OABI) Stock Is Up 5.76%
As of Tuesday, August 18, OmniAb, Inc.’s OABI share price has surged by 5.76%, which has investors questioning if this is right time to sell.Michael Rose
Why OmniAb, Inc.’s (OABI) Stock Is Up 20.56%
As of Monday, August 17, OmniAb, Inc.’s OABI share price has surged by 20.56%, which has investors questioning if this is right time to sell.Jenna Brashear
Why OmniAb, Inc.’s (OABI) Stock Is Up 17.85%
As of Monday, August 17, OmniAb, Inc.’s OABI share price has surged by 17.85%, which has investors questioning if this is right time to sell.Omar Beirat
Financial Summary
| Share Statistics | OABI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $625.2 | $3,076.5 | 39% |
|
| Shares Out (Mil) | 128.8 | 96.5 | 67% |
|
| Institutional Ownership | 76.0% | 90.0% | 46% |
|
| Float (Mil) | 118.2 | 71.5 | 64% |
|
| Beta | 1.22 | 1.22 | 72% |
|
| Avg Daily Volume (000s) | 3,470 | 710 | 89% |
|
| Price Change (52-week) |
112.9% | 89.4% | 92% |
|
| Growth | OABI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (4.3%) | 7.8% | 9% |
|
| Net Income (5yr) | (29.8%) | (13.7%) | 14% |
|
| EPS (5yr) | na | 0.7% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 4 | |
| Current EPS | ($0.130) | ($0.366) | ($0.295) | |
| Month Ago EPS | ($0.118) | ($0.416) | ($0.323) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.118) | ($0.416) | ($0.323) | |
| Year/Year Chg | 188.9% | (35.8%) | (74.6%) | |
| Financials | OABI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $39 | $800 | 18% |
|
| Net Income (TTM) (Mil) | ($44) | ($31) | 17% |
|
| EPS (TTM) | ($0.354) | ($0.300) | 30% |
|
| Operating Cash Flow (TTM) (Mil) | ($18) | $47 | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $15 | $270 | 31% |
|
| Enterprise Value (Q1) (Mil) | $415 | $3,795 | 33% |
|
| Valuation | OABI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.40 | 3.68 | 57% |
|
| P/E | na | 39.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.5 | na |
|
| Ratios | OABI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 98.3% | 47.7% | 96% |
|
| Net Margin | (115.1%) | (3.2%) | 7% |
|
| ROA | (15.1%) | (4.3%) | 22% |
|
| ROE | (17.0%) | (7.9%) | 24% |
|
| Liabilities to Assets | 10.3% | 42.0% | 6% |
|
| F-Score | 5 | 5 | 50% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Driehaus Screen
Factors: Size, Momentum, Growth, Earnings Estimates
Classic momentum approach that seeks out stocks that are rapidly rising in price with the belief that the rising price will attract other investors.
| Performance Since Inception: | 13.3% |
| +/- S&P 500: | +5.8 |
